NCT02502734View on ClinicalTrials.gov

Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 7, 2015

Primary Completion Date

December 21, 2015

Study Completion Date

December 21, 2015

Conditions
Asthma
Interventions
DRUG

Fluticasone furoate

FF will be provided as a dry powder inhaler containing 50 μg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.

DRUG

Placebo

Placebo will be provided as dry powder inhaler containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.

DRUG

Salbutamol

Salbutamol will be provided as a inhaler.

Trial Locations (1)

8900

GSK Investigational Site, Randers

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma | Biotech Hunter | Biotech Hunter